Who
Cory S. Freedland
Director
Company insider
Files Form 4 as: Director, Neurogene.
In numbers
- Trades disclosed
- 5
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 16 Jan 2024
- Last trade
- 20 Feb 2026
- Last filed
- 24 Feb 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Feb 2026filed 24 Feb 2026 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,050 at $0.00 | filing |
| 20 Feb 2026filed 24 Feb 2026 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,050 at $0.00 | filing |
| 12 Jun 2025filed 13 Jun 2025 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,050 at $0.00 | filing |
| 14 Jun 2024filed 17 Jun 2024 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,700 at $0.00 | filing |
| 16 Jan 2024filed 18 Jan 2024 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,400 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.